Research

Clinical Trials
  Breast
  Ovarian
  Colon
  Resources
  FAQ

TVG in the News

Publications

TVG Newsletter

Open House

Staff

Contact Us

You Can Help

TVG Intranet





Title
 
 
Study Design
Expanding HER2 specific T cells ex vivo and administering these cells to patients in escalating doses.
 
Study Contact
Stephanie Parker | 866.932.8588 | E-Mail
 
Patient Population
  1. Must be pre-immunized with a HER2-specific vaccine through a vaccine protocol (Approved by UW)
  2. HER2-neu overexpressing disease
  3. Progressive metastatic breast, ovarian, or non-small cell lung cancer
  4. Not considered curable by conventional therapies, including trastuzumab
  5. Measurable extraskeletal disease
Number of Patients: This study will accrue a maximum of 10 patients. 2 Arms with 5 patients per Arm.
 
Patients Visits

  1. First visit to collect lymphocytes & consent for study
  2. 3 infusions on Days 1, 10 & 20
  3. Follow-up visit on Day 40
  4. Blood draw 1 month post infusion #3
  5. Blood draw every 2 months for the 1st year
Other Procedures

  1. CT Scans
  2. Chemotherapy pre-meds
  3. Low dose cyclophosphamide (Cytoxan) to deplete T-regs
  4. Possible MUGA (if not done w/in 30 days of T-cell infusion
Objectives
Primary:
  1. Feasibility of HER2 T cells expansion
  2. Toxicity associated with HER2 T-cell infusion
Secondary:
  1. Potential anti-tumor effects of HER2 specific T cells
  2. To determine the persistence of DNA at the site of vaccination
  3. Persistence of immune response
Start Date: June 2003
 
Study Location: University of Washington Medical Center | 1959 NE Pacific Street | Seattle, WA 98195
 
Current Enrollment: 50%
 
Related Publications
Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming
Dang Y, Knutson KL, Goodell V, dela Rosa C, Salazar LG, Higgins D, Childs J, Disis ML
Clin Cancer Research 13(6):1883-91, 2007
 
Scientific Description
 
ClinicalTrials.gov Identifier: NCT00228358
 
Page last updated 01/26/2012